Psoriatic Disease
Cyltezo 'paid the price' for interchangeable biosimilar approval: Will it be worth it?
In October, Boehringer Ingelheim’s adalimumab-adbm secured a landmark FDA approval as the first interchangeable biosimilar to AbbVie’s blockbuster drug, Humira — but, as rivals scramble for second place, will the designation be worth the price?
Dactylitis signals greater disease burden in early psoriatic arthritis
Dactylitis indicates a more severe disease phenotype independently linked to increased disease burden, with greater bone erosion, in early DMARD-naïve psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.
FDA approves Cosentyx for children with juvenile PsA, enthesitis-related arthritis
The FDA has approved secukinumab for the treatment of active psoriatic arthritis in patients aged 2 years and older, and for active enthesitis-related arthritis in those aged 4 years and older.
Upadacitinib effective as monotherapy, in combination with non-biologics for PsA
Upadacitinib demonstrates comparable efficacy and safety as monotherapy or in combination with non-biologic disease-modifying antirheumatic drugs in patients with psoriatic arthritis, according to data published in Rheumatology.
Coherus’ Yusimry nabs FDA approval as seventh Humira biosimilar in cramped market
The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the biologic product, the latest in an increasingly crowded biosimilar logjam set to release in 2023.
Elevated spine symptoms in psoriatic arthritis linked to worse quality of life, disease activity
Patients with self-reported elevated spine symptoms in psoriatic arthritis, with or without a diagnosis of axial disease, had worse quality of life and disease activity overall versus patients without axial manifestations, according to data.
FDA approves Rinvoq for patients with active psoriatic arthritis
The FDA has approved Rinvoq, a 15-mg, once-daily oral JAK inhibitor, for the treatment of adults with active psoriatic arthritis who have had an inadequate response, or intolerance to, TNF inhibitors, according to an AbbVie press release.
Guselkumab sustains skin, joint improvements in biologic-naïve PsA through 2 years
Guselkumab is associated with durable improvements in multiple psoriatic disease domains through 2 years, with no new safety findings, in patents who are biologic-naïve, according to data published in Arthritis & Rheumatology.